ImmunoGen competitors

Ron Cohen, M.D., President and Chief Executive Officer, founded Acorda Therapeutics, Inc. in 1995. Previously he was a principal in the startup and an officer of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation. Dr. Cohen received his B.A. with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed his residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine. Dr. Cohen is a member of the Executive Committee and Vice Chair of the Health Section of the Biotechnology Industry Organization (BIO), and serves on the Board of Directors of Dyax Corp. He previously served as Director and Chairman of the New York Biotechnology Association (NYBA). He also serves as a member the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University’s Alumni Medal for Distinguished Service. Dr. Cohen was named NeuroInvestment’s (now called NeuroPerspective) CEO of the Year and was recognized by PharmaVoice Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry. He is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region and is an inductee of the National Spinal Cord Injury Association’s “Spinal Cord Injury Hall of Fame.” In 2010, Dr. Cohen was recognized by the New York Biotechnology Association as the NYBA “The Cure Starts Here” Business Leader of the Year.

Yvonne Greenstreet is a COO at ALNYLAM PHARMACEUTICALS, INC..

James E. Brown, D.V.M. co-founded DURECT in February 1998 and has served as President, Chief Executive Officer and a Director since June 1998. He previously worked at ALZA Corporation as Vice President of Biopharmaceutical and Implant Research and Development from June 1995 to June 1998. Prior to that, Dr. Brown held various positions at Syntex Corporation, a pharmaceutical company, including Director of Business Development from May 1994 to May 1995, Director of Joint Ventures for Discovery Research from April 1992 to May 1995, and held a number of positions including Program Director for Syntex Research and Development from October 1985 to March 1992. Dr. Brown holds a B.A. from San Jose State University and a D.V.M. (Doctor of Veterinary Medicine) from the University of California, Davis where he also conducted post-graduate work in pharmacology and toxicology.

I'm the chairman and CEO of Eli Lilly and Company, after holding management roles in the U.S., Canada and China, as well as running Lilly’s largest business unit. Before I joined Lilly in 1996, I worked as an account rep at IBM. I'm on the board of Adobe, and I'm chairman of the board of the Pharmaceutical Research and Manufacturers of America (PhRMA). I also serve on the board of the Central Indiana Corporate Partnership. I'm a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) CEO Steering Committee, The Business Council, Business Roundtable and the National Council for Expanding American Innovation (NCEAI). I serve on the Riley Children’s Foundation’s board of governors. I am a digital media spokesperson for Lilly and discuss topics related to our company, our business and the health care environment. We operate in a highly regulated environment, and only designated employees can discuss our products or pipeline. If you need information about our products or have questions or concerns, please visit these resources: https://e.lilly/guidelines

Michael Morrissey is a President/CEO at EXELIXIS, INC.; Board Member at EXELIXIS, INC.; and Board Member at XW LABORATORIES INC and is based in Danville, California. He has experience at Schering AG and has worked as VP:Discovery Research at Berlex Biosciences; Senior Scientist at Novartis; and Senior VP:Discovery at EXELIXIS, INC.. Michael studied at Harvard University and University of Wisconsin Oshkosh.

Michael Pehl is a CEO at GEMoaB Monoclonals GmbH and is based in Dresden, Free State of Saxony, Germany. He has worked as General Manager Germany at CELGENE CORP, President and CEO at IMMUNOMEDICS INC, and Senior VP:Global Marketing at CELGENE CORP. Michael works or has worked at Amgen. He attended LMU and Ludwig-Maximilians-University of Munich.

John L. Higgins has over 14 years of corporate development, financing, strategic planning, commercialization, and investment banking experience in the biopharmaceutical industry. He is the chief executive officer of [Ligand Pharmaceuticals](https://www.crunchbase.com/organization/ligand-pharmaceuticals#/entity), a biotechnology company that focuses on the discovery and early-stage development of pharmaceuticals for medical needs in the United States. Prior to joining Ligand, Higgins was the chief financial officer; and executive vice president of finance, administration, and corporate development at Connetics Corporation, a public specialty pharmaceutical company, until its acquisition by Stiefel Laboratories, Inc. in 2006. During his service period of nearly 10 years at Connetics, he played a key leadership role in numerous strategic initiatives, including major acquisitions, divestitures, multiple product and technology licensing transactions, and financings. Prior to joining Connetics, Higgins was the executive vice president of corporate development at BioCryst Pharmaceuticals, Inc. and was a member of the health care investment banking team at Dillon, Read & Company, Inc. He has served numerous public and private corporate boards and currently is a director at BioCryst Pharmaceuticals, Inc. where he serves as chairman of the audit committee. Higgins earned a bachelor’s degree in Economics from Colgate University.

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Howard Robin joined Nektar Therapeutics in January 2007. He has more than 25 years of successful biopharmaceutical experience managing clinical development and commercial operations. Most recently, Mr. Robin served as President and Chief Executive Officer of Sirna Therapeutics, a clinical-stage biotechnology company pioneering RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis C, asthma, respiratory syncytial virus (RSV) and Huntington's disease. During his tenure at Sirna, Mr. Robin successfully re-launched the company and created significant shareholder value that led to its acquisition by Merck for $1.1 billion. Prior to Sirna, Mr. Robin spent 20 years at Berlex Laboratories, the U.S. pharmaceutical subsidiary of the German pharmaceutical firm Schering AG. From 1991 to 2001, he served as corporate vice president and general manager of their U.S. Therapeutics division and was responsible for the development of drugs, such as Betaseron® (Interferon beta-1b) for multiple sclerosis and Fludara® (fludarabine phosphate) for chronic lymphocytic leukemia, generating annual global sales in excess of $800 million. He also served as a member of the Executive Committee. Prior to that, he was vice president of Finance and Business Development and CFO of Berlex. Earlier in his career, Mr. Robin was a senior associate with Arthur Andersen and Co. Mr. Robin serves as a director of the Biotechnology Industry Organization, the world's largest biotechnology industry trade organization. Mr. Robin holds a B.S. in Accounting and Finance from Fairleigh Dickinson University in New Jersey and serves as a member of its Board of Trustees.

Albert Bourla (Greek: Άλμπερτ Μπουρλά, born) is a Greek veterinarian and the chairman and chief executive officer of Pfizer, an American pharmaceutical company. He joined the company in 1993 and has held several executive roles across Pfizer's divisions. Prior to becoming chief executive officer, Bourla served as chief operating officer.